A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension Clinical Trial

Official title:

An Open-Label Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04791514
• Other study ID #: INS1009-201
• Status: Terminated
• Phase: Phase 2
• Start date: March 29, 2022
• Est. completion date: August 26, 2022

Study information

• Verified date: August 2023
• Source: Insmed Incorporated
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial hypertension (PAH).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: August 26, 2022
• Est. primary completion date: August 26, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant must be = 18 years of age at the time of signing the informed consent
• Participants must have a diagnosis of World Health Organization Group 1 Pulmonary Hypertension (PH) (PAH) with the following characteristics

1. Etiology of idiopathic, heritable, drug/toxin-induced or connective tissue disease (CTD)-related PAH

2. Right heart catheterization with the following hemodynamic findings:

• Mean pulmonary arterial pressure (mPAP) > 20 mmHg at rest,
• Pulmonary capillary wedge pressure (PCWP) = 15 mmHg, and
• Pulmonary vascular resistance (PVR) of = 3 Wood Units (WU)
• No change in pulmonary hypertension medications (eg, ambrisentan, bosentan, macitentan, sildenafil, tadalafil, riociguat) or dosage for at least 90 days prior to Screening
• No change in diuretic use or dosage for at least 30 days prior to Screening
• Body mass index (BMI) within the range 18.0 - 32.0 kg/m^2 (inclusive)
• Male participants: Male participants and their female partners of childbearing potential must agree to use highly effective contraception from Study Day 1 to at least 90 days after dosing
• Female participants: Women of child-bearing potential (WOCPB, defined as premenopausal, not surgically sterile for at least 3 months prior to Screening) must use a highly effective contraception method and agree to be tested for pregnancy from at Screening, Baseline, and 30 days after dosing
• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.

Exclusion Criteria:

• Any PH other than idiopathic, hereditary, drug/toxin-induced, or connective tissue disease (CTD) associated PAH (eg, congenital heart disease-associated PAH, portal hypertension-associated PAH, PH belonging to Groups 2 through 5)
• Allergy, or documented hypersensitivity or contraindication, to the ingredients of treprostinil palmitil inhalation powder (TPIP) or treprostinil (TRE)
• Previous intolerance to prostacyclin analogs or receptor agonists (eg, selexipag) per investigator discretion
• History of anaphylaxis or previously documented hypersensitivity reaction to any drug per Investigator discretion
• History of heart disease including left ventricular ejection fraction (LVEF) = 40% or clinically significant valvular, constrictive, or atherosclerotic heart disease (myocardial infarction, etc)
• Active liver disease or hepatic dysfunction manifested as:

1. Elevated liver function test results (ALT or AST > 2 × ULN) at Screening

2. Bilirubin > 1.5 × ULN (isolated bilirubin > 1.5 × ULN; ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%) at Screening.

3. Known hepatic or biliary abnormalities, not including Gilbert's syndrome or asymptomatic gallstones at Screening.

• History of HIV infection/positive HIV serology test result at Screening
• History of active/chronic Hepatitis B or C/ positive hepatitis B or C serology test result at Screening
• History of abnormal bleeding or bruising
• Known or suspected immunodeficiency disorder, including history of invasive opportunistic infections (eg, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immune-compromised status, as judged by the investigator
• Active and current symptomatic infection by SARS CoV 2
• Participants with current or recent (past 4 weeks) lower respiratory tract infection
• History of malignancy in the past 5 years, with exception of completely treated in situ carcinoma of the cervix and completely treated non-metastatic squamous or basal cell carcinoma of the skin
• Participants receiving triple combination therapy for PAH consisting of endothelin receptor agonists, phosphoesterase type 5 inhibitors, and guanylate cyclase stimulators (riociguat)
• Participants receiving prostanoids/prostacyclin agonists
• Participants receiving potent CYP2C8 inhibitors, such as gemfibrozil
• Have participated in any other interventional clinical studies within 30 days of Baseline
• Current or history of substance and/or alcohol abuse
• Current user of cigarettes or e-cigarettes
• Pregnant or breastfeeding

Related Conditions & MeSH terms

• Familial Primary Pulmonary Hypertension
• Hypertension
• Pulmonary Arterial Hypertension
• Respiratory Aspiration

Intervention

Drug:
• Treprostinil Palmitil
Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler

Locations

Country	Name	City	State
United States	USA002	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Insmed Incorporated

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Who Experience a Treatment Emergent Adverse Event (TEAE)		Up to 150 days
Secondary	Change From Baseline in Pulmonary Vascular Resistance (PVR) After TPIP Administration		Day 1: Pre-treatment (Baseline), 8 and 24 hours post-treatment
Secondary	Maximum Observed Concentration (Cmax) of Treprostinil (TRE) in Plasma		Pre-dose and multiple timepoints post-dose up to Day 2
Secondary	Time to Maximum Concentration (Tmax) of Treprostinil (TRE) in Plasma		Pre-dose and multiple timepoints post-dose up to Day 2
Secondary	Area Under the Concentration-time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of Treprostinil (TRE) in Plasma		Pre-dose and multiple timepoints post-dose up to Day 2
Secondary	Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-8) of Treprostinil (TRE) in Pasma		Pre-dose and multiple timepoints post-dose up to Day 2
Secondary	Elimination Half-life (t1/2) of Treprostinil (TRE) in Plasma		Pre-dose and multiple timepoints post-dose up to Day 2